MULTIPLE MYELOMA

This early-stage study tested a new drug called tasquinimod in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find a safe dose and see how well it worked alone or with standard therapy. The trial was stopped early, so results a…

This study looked at two different high-dose chemotherapy treatments given before a stem cell transplant in people aged 65 and older with multiple myeloma. The goal was to see if adding the drug bortezomib to the standard chemotherapy melphalan could help patients live longer wit…

This early-stage study aimed to find the best dose and check the safety of combining alnuctamab and mezigdomide for people with multiple myeloma that had come back or stopped responding to treatment. Only 4 participants were enrolled before the study was stopped early. The main g…

This study tested a new drug, elranatamab, combined with other cancer treatments for people with multiple myeloma that had returned or stopped responding to prior therapies. The goal was to find the best dose and see if the combination helped control the disease. The study was te…

This early-phase study tested a new type of immunotherapy called CAR-T cells that target a protein called BCMA on myeloma cells. The treatment involved taking a patient's own immune cells, engineering them to attack the cancer, and giving them back. The study aimed to check safet…

This study looked at whether adding ixazomib to lenalidomide and dexamethasone could help control multiple myeloma in people who had already received three cycles of a bortezomib-based treatment. About 141 adults took part. The goal was to see how long the disease stayed under co…

This early-stage study tested a new drug called modakafusp alfa, given through a vein, in combination with other treatments for adults with multiple myeloma. The main goals were to find the safest dose and to monitor side effects. The trial was terminated early, but it gathered i…

This study tested a new treatment called LCAR-B38M CAR-T cells in 123 Chinese adults with multiple myeloma that had returned or not responded to at least three prior therapies. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on myeloma cell…

This study tested a new drug called modakafusp alfa in people with multiple myeloma that had come back or stopped responding to other treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped early, but the results help researcher…

This study tested a combination of two cancer drugs, ixazomib and daratumumab, without using steroids (dexamethasone) in patients aged 65 and older whose multiple myeloma had returned after prior treatment. The goal was to see if this approach could effectively control the diseas…

This study looked at whether a donor stem cell transplant could help people with multiple myeloma whose cancer came back after initial treatment. It compared the transplant to continuing standard drug therapy. The study was stopped early and only enrolled 28 people, so results ar…

This study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It included 200 people and aimed to see how many survived one year after the transplant. The approach is intense and mean…

This study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could help control high-risk multiple myeloma and lymphoma. It enrolled 46 adults aged 18-80. The main goal was to check safety, but the study was terminated early, so…

This study tested an experimental drug (INCB000928) for anemia in people with myelodysplastic syndromes (MDS) or multiple myeloma who needed blood transfusions or had anemia symptoms. The goal was to check safety and find the right dose. The study was stopped early, and only 22 p…

This study tested a new treatment called PHE885 for adults with multiple myeloma that came back or didn't respond to at least three prior therapies. PHE885 is a type of CAR-T cell therapy that targets a protein called BCMA on myeloma cells. The goal was to see how well it shrinks…

This study tested a new drug, CC-92480, alone or with dexamethasone, in 200 people with multiple myeloma that returned after at least three prior treatments. The goal was to check safety, dosing, and how well it worked. The trial was terminated early, so results are limited.

This study tested a new drug (modakafusp alfa) combined with a standard treatment (daratumumab) in 15 people with multiple myeloma that had returned or stopped responding to prior therapies. The main goals were to check safety and find the best dose. The study was terminated earl…

This study tested a cell therapy called bb2121 (Ide-cel) combined with other drugs in 21 adults with multiple myeloma that had returned or stopped responding to treatment. The goal was to find the safest dose and see if the combinations helped control the cancer. The trial was te…

This early-phase study tested whether the drug belantamab mafodotin (Blenrep) could help prevent multiple myeloma from returning after a stem cell transplant. Six participants with relapsed or refractory myeloma received the drug as maintenance therapy. The study focused on safet…

This study tested a sensory rehabilitation program for people who lost their sense of smell or taste after chemotherapy for blood cancers like multiple myeloma or lymphoma. The program aimed to improve these senses and boost quality of life, nutrition, and mental well-being. Only…

This study looked at why some multiple myeloma patients develop shortness of breath when taking the drug carfilzomib. Researchers used an FDA-approved device called EndoPAT to check blood vessel health and see if it relates to breathing problems. The goal was to find ways to pred…

This study aimed to track four bone-related substances in the blood and urine of multiple myeloma patients receiving intravenous bisphosphonates, a common bone-strengthening treatment. Researchers planned to follow patients for up to 12 months to see how these markers changed ove…

This study was a registry that followed over 3,000 adults newly diagnosed with multiple myeloma to understand how the disease is managed in everyday medical practice. Researchers collected information on patient backgrounds, treatments, and outcomes without providing any new ther…